FindMyKOL
Clinical trialNCT03064126CompletedPhase 3Interventional

RANGER™ Paclitaxel Coated Balloon vs Standard Balloon Angioplasty

NCT03064126 is a phase 3 interventional trial sponsored by Boston Scientific Corporation. As of 18 Nov 2026, it is completed. It studies Paclitaxel in Artery Diseases, Peripheral, Atherosclerosis and 3 more conditions. The registry lists an enrollment of 440 participants at 67 sites in 6 countries. The registry lists a start date of 2 Mar 2017 and a primary completion date of 18 Nov 2019.

SponsorBoston Scientific CorporationEnrollment440Artery Diseases, PeripheralAtherosclerosisOcclusive Arterial DiseasePeripheral Artery DiseasePlaque, Atherosclerotic
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT03064126
FieldValue
Registry IDNCT03064126
StatusCompleted
PhasePhase 3
Study typeInterventional trial
Lead sponsorBoston Scientific Corporation
Enrollment440
Registered sites67
Countries6
ConditionsArtery Diseases, Peripheral, Atherosclerosis, Occlusive Arterial Disease, Peripheral Artery Disease and Plaque, Atherosclerotic
DrugsPaclitaxel
Start2 Mar 2017
Primary completion18 Nov 2019
Study completion25 Oct 2023
Last update posted29 Oct 2024

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

To evaluate the safety and effectiveness of the Ranger™ Paclitaxel Coated Balloon for treating lesions located in the superficial femoral and proximal popliteal arteries (SFA/PPA). Long Balloon substudy: To evaluate the safety and effectiveness of the Boston Scientific Corporation (BSC) Ranger™ Paclitaxel Coated Balloon in the 120, 150 and 200 mm lengths for treating Superficial Femoral Artery (SFA) and/or Proximal Popliteal Artery (PPA) lesions.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

67 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Alabama, United States1 site
  • Thomas Hospital

    Fairhope

Colorado, United States1 site
  • Rocky Mountain Regional Va Medical Center

    Aurora

Connecticut, United States1 site
  • the Vascular Experts

    Stratford

Delaware, United States1 site
  • Christiana Hospital

    Newark

District of Columbia, United States1 site
  • Washington Hospital Center

    Washington D.C.

Florida, United States5 sites
  • South Florida Vascular Associates

    Coconut Creek

  • North Florida Regional Medical Center

    Gainesville

  • Mount Sinai Medical Center

    Miami Beach

  • Adventhealth Orlando

    Orlando

  • Adventhealth Sebring

    Sebring

Georgia, United States1 site
  • Wellstar Hospitals

    Marietta

Hawaii, United States1 site
  • Kaiser Foundation Hospitals

    Honolulu

Indiana, United States2 sites
  • St. Joseph Hospital

    Fort Wayne

  • Community Hospital

    Munster

Kentucky, United States1 site
  • King's Daughters Medical Center - Kentucky Heart Institute

    Ashland

Louisiana, United States1 site
  • Terrebonne General Medical Center

    Houma

Minnesota, United States2 sites
  • Mercy Hospital

    Coon Rapids

  • United Heart and Vascular Clinic

    Saint Paul

New Jersey, United States2 sites
  • Hackensack University Medical Center

    Hackensack

  • Jersey Shore University Medical Center

    Neptune City

New York, United States2 sites
  • Mount Sinai Medical Center

    New York

  • Staten Island University Hospital

    Staten Island

North Carolina, United States2 sites
  • Rex Hospital

    Raleigh

  • Coastal Carolina Surgical Associates

    Wilmington

Ohio, United States4 sites
  • Bethesda North Hospital

    Cincinnati

  • Ohio State University Medical Center

    Columbus

  • Premier Cardiovascular Institute

    Dayton

  • Northeast Ohio Vascular Associates, Inc.

    Willoughby

Oregon, United States1 site
  • St. Charles Medical Center

    Bend

Pennsylvania, United States1 site
  • Temple University

    Philadelphia

South Carolina, United States1 site
  • University Medical Center-Greenville Memorial Hospital

    Greenville

Tennessee, United States1 site
  • Turkey Creek Medical Center

    Knoxville

Texas, United States7 sites
  • North Park Heart & Vascular Center

    Dallas

  • Cardiology Clinic of San Antonio

    Live Oak

  • Texas Tech University Health Sciences Center

    Lubbock

  • North Dallas Research Associates

    McKinney

  • Thr Presbyterian Plano

    Plano

  • the Heart Hospital Baylor Plano

    Plano

  • Tyler Cardiac and Endovascular Center

    Tyler

Utah, United States1 site
  • Davis Hospital and Medical Center

    Layton

West Virginia, United States1 site
  • West Virginia University Hospitals

    Morgantown

Wisconsin, United States1 site
  • Aspirus Heart and Vascular Institute

    Wausau

Japan12 sites
  • Kokura Memorial Hospital

    Kitakyushu, Fukuoka

  • Iwaki City Medical Center

    Iwaki, Fukushima

  • Tokeidai Memorial Hospital

    Sapporo, Hokkaido

  • Kansai Rosai Hospital

    Amagasaki, Hyōgo

  • Saiseikai Yokohama-City Eastern Hospital

    Yokohama, Kanagawa

  • Sendai Kousei Hospital

    Sendai, Miyagi

  • Kishiwada Tokushukai Hospital

    Kishiwada, Osaka

  • Kasukabe Chuo General Hospital

    Kasukabe, Saitama

  • Saiseikai Central Hospital

    Minato, Tokyo

  • Kyoto Katsura Hospital

    Kyoto

  • Morinomiya Hospital

    Osaka

  • Osaka Saiseikai Nakatsu Hospital

    Osaka

Canada4 sites
  • Peter Lougheed Centre

    Calgary, Alberta

  • Hamilton General Hospital

    Hamilton, Ontario

  • Fleurimont Hospital

    Sherbrooke, Quebec

  • Hopital Saint - Francois D'Assise

    Québec

Austria3 sites
  • Medizinische Univ.-Kliniken Graz

    Graz

  • Allgemeines Krankenhaus Akh

    Vienna

  • Hanusch-Krankenhaus

    Vienna

Belgium3 sites
  • Ziekenhuis Oost Limburg

    Genk

  • Universitair Ziekenhuis Gent

    Ghent

  • Regionaal Ziekenhuis Heilig Hart Tienen

    Tienen

New Zealand3 sites
  • Auckland City Hospital

    Auckland

  • Clinical Trials Nz

    Hamilton

  • Middlemore Hospital

    Otahuhu

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT03064126

Each answer restates registry values shown on this page.

What is NCT03064126?

NCT03064126 is a phase 3 interventional trial sponsored by Boston Scientific Corporation. It studies Paclitaxel in Artery Diseases, Peripheral, Atherosclerosis and 3 more conditions.

Who leads NCT03064126?

The registry names Ravish Sachar, MD (principal investigator, University of North Carolina - Rex Hospital) and Thomas Zeller, MD (principal investigator, Universitaets-Herzzentrum) as overall officials.

Where does NCT03064126 run?

The registry lists 67 sites in 6 countries. Most sites are in these countries: United States (42), Japan (12) and Canada (4).

Which drugs does NCT03064126 study?

The registered drug and biological interventions are Paclitaxel.

When did NCT03064126 end?

The registry lists a primary completion date of 18 Nov 2019 and a study completion date of 25 Oct 2023. The sponsor last updated the record on 29 Oct 2024.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 18 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.